← Back to Search

UPLYFT for Lymphoma

N/A

Recruiting

Led By Oreofe O Odejide, MD, PhD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Lymphoma Survivors Phase 1 and 2: In complete remission after first line of treatment

Lymphoma Survivors Phase 1 and 2: Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)

Must not have

Lymphoma Survivors Phase 1: Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen)

Lymphoma Survivors Phase 2: Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing an intervention to help improve quality of life and reduce lymphoma-related worries for survivors.

Who is the study for?

This trial is for adults over 18 who have been treated for lymphoma and are in remission but still experience significant fear of cancer recurrence. They must be within 3 to 24 months post-treatment, have access to a computer, and not have other untreated major psychiatric disorders or concurrent malignancies.

What is being tested?

UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) is being tested. It's an intervention designed to help lymphoma survivors improve their quality of life by providing information on survivorship and tools to manage worries about the disease returning.

What are the potential side effects?

Since UPLYFT involves informational support rather than medication, traditional side effects like those seen with drugs aren't expected. However, discussing fears related to cancer can potentially cause emotional discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am in complete remission from lymphoma after my first treatment.

Select...

I was diagnosed with a type of lymphoma.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have untreated mental health conditions like psychosis, bipolar, or borderline personality disorder.

Select...

I do not have untreated mental health conditions like psychosis, bipolar, or borderline personality disorder.

Select...

I have another type of cancer besides lymphoma.

Select...

I am under 18 years old and a lymphoma survivor.

Select...

I am an adult.

Select...

I have lymphoma and another type of cancer at the same time.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Feasibility: Data Collection Completion Rate

Feasibility: Enrollment Rate

Feasibility: Program Session Completion Rate

Secondary study objectives

Acceptability: Disenrollment Rate

Acceptability: Satisfaction Rate

Preliminary efficacy: Anxiety Change

+4 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Group I: UPLYFT PilotExperimental Treatment1 Intervention

Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program. Participants will be randomized 1:1 to either UPLYFT or usual care.

Group II: Lymphoma Survivors Field TestExperimental Treatment1 Intervention

A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.

Group III: Clinicians InterviewsExperimental Treatment1 Intervention

Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.

0 / 8Eligibility criteria met